Overcoming Resistance of Human Non-Hodgkin’s Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors

Lignende værker

• Combination of celecoxib (Celebrex(®)) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin’s lymphomas
  af: Dinh, Tam NM, et al.
  Udgivet: (2017)
• Histone deacetylase inhibitors in Hodgkin lymphoma
  af: Buglio, Daniela, et al.
  Udgivet: (2010)
• Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor
  af: Jazirehi, Ali R, et al.
  Udgivet: (2014)
• CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphomas
  af: Onea, Alexandra S, et al.
  Udgivet: (2016)
• The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
  af: Klein, Jan M., et al.
  Udgivet: (2013)